1.Hyperglycemia Promotes Human Gastric Carcinoma Progression Via Aquaporin 3 2.Preoperative Serum CEA And CA19-9 Levels In Gastric Cancer: A Single Tertiary Hospital Study Of 1075 Cases

Background and AimHyperglycemia plays an important role in the development of gastric carcinoma(GC). Aquaporin 3(AQP3) had been demonstrated to be over-expressed in GC and involved in carcinogenesis and progression of GC. Hyperglycemia promotes AQP3 expression in human peritoneal mesothelial cells. However, whether hyperglycemia could promote the progression of human GC via inducing AQP3 expression of GC is unknown. This study was aimed to investigate whether hyperglycemia promotes progression of GC via AQP3.Methods978 patients with GC were consecutively enrolled in this study, and the correlation between their fasting plasma glucose(FPG) and clinicopathological features was evaluated. AQP3 was detected by immunohistochemistry in human GC specimens. Western blotting assays and real time-q PCR were used to evaluate the change of AQP3 expression in the human GC MGC803 and SGC7901 cell lines after co-culture with HG. Transwell migration assays and CCK-8 assays were to test migration and proliferation of GC cells.ResultsHyperglycemia(FPG≥6.1 mM) correlated with tumor size, tumor location and p TNM stage in patients with GC. AQP3 expression in tumor tissue was associated with FPG levels of patients with GC. HG up-regulated AQP3 expression in a doseor time- dependent way in human GC cells. HG could promote the migration of GC cells markedly, and AQP3 knockdown with si RNA could abrogate the up-regulation of HG on cell migration significantly. However, HG treatment inhibited the cell proliferation, and AQP3 knockdown significantly intensify the inhibition of HG on cell proliferation. Signal studies indicated that the ERK, PI3K/AKT signaling pathways were involved in HG regulation on AQP3 expression in human GC cells. ConclusionHyperglycemia promotes GC progress via AQP3. This improves our understanding of the mechanism of hyperglycemia-induced carcinogenesis, and provides a potential therapeutic strategy for GC.Objective: To reevaluate the clinical impact of preoperative serum CEA and CA19-9 on resectable GC.Methods: 1075 consecutive cases with gastric adenocarcinoma were obtained retrospectively from January 2012 and December 2013 in a single tertiary hospital. The relationships between serum CEA, CA19-9 and clinicopathologic features of gastric cancer were investigated.Results: The positive rate of preoperative serum CEA and CA19-9 was 22.4% and 12.3% respectively. Preoperative serum CEA level correlated with depth of invasion, lymph node involvement, p TNM stages and lymphovascular invasion significantly, and CA19-9 level also presented remarkable association with these features except lymphovascular invasion. Both CEA and CA19-9 positivity significantly and positively correlated with depth of invasion, nodal involvement, p TNM stage, lymphovascular invasion, tumor size and tumor location. Serum CEA positivity was significantly correlated with serum CA19-9 positivity. Stratified analyses according to gender or tumor location showed preoperative CEA or CA19-9 had different association with clinicopathologic features in different gender subgroups or location subgroups. The preoperative serum CA19-9 positivity may be more meaningful for tumor size rather than CEA.Conclusions: Preoperative serum CEA and CA19-9 correlated with disease progression of GC, and may have application in aiding more accurate estimation of tumor progression, decision of treatment choice and prognosis evaluation.